ArticleFrontiers in microbiology2026
Integrated analysis reveals microbiota-metabolite-immune alterations associated with coronary heart disease.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between gut microbiota, metabolites, immune environment, and coronary heart disease (CHD) remains incompletely understood. Methods: This study enrolled 100 non-CHD controls and 302 CHD patients, including 102 with acute coronary syndrome (ACS), 100 with chronic stable angina pectoris (CSAP), and 100 with ischemic cardiomyopathy (ICM). Gut microbiota was analyzed via 16S rRNA gene sequencing, plasma trimethylamine N-oxide (TMAO) and phenylacetylglutamine (PAGln) were measured by mass spectrometry, and flow cytometry was used to assess T, B, and natural killer (NK) lymphocyte subsets. Results: CHD patients showed reduced gut microbial richness (Chao1 and ACE indices, Conclusion: CHD is associated with gut microbiota dysbiosis, and reduced microbial richness, which may influence immune homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.